BEAM-301: Single dose of BEAM-301 administered by IV for glycogen storage disease type i

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Dec 2024: Trial started, NCT06735755
  2. 16 Dec 2024: Trial registered, NCT06735755

The trials

NCT06735755: A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)

State
Under way
Phase
Phase 1 and Phase 2
People
36 planned
Started
6 Dec 2024
Primary completion
30 Dec 2027
Arms
BEAM-301
Results
None posted
  1. 6 Dec 2024: Trial started
  2. 16 Dec 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.